Annual EBIT
-$83.61 M
+$15.98 M+16.05%
31 December 2023
Summary:
UroGen Pharma annual earnings before interest & taxes is currently -$83.61 million, with the most recent change of +$15.98 million (+16.05%) on 31 December 2023. During the last 3 years, it has risen by +$43.13 million (+34.03%). URGN annual EBIT is now -10577.32% below its all-time high of $1.01 million.URGN EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
-$20.86 M
+$9.04 M+30.24%
30 September 2024
Summary:
UroGen Pharma quarterly earnings before interest & taxes is currently -$20.86 million, with the most recent change of +$9.04 million (+30.24%) on 30 September 2024. Over the past year, it has dropped by -$2.79 million (-15.43%). URGN quarterly EBIT is now -250.07% below its all-time high of $13.90 million, reached on 31 December 2016.URGN Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
-$99.13 M
-$2.79 M-2.89%
30 September 2024
Summary:
UroGen Pharma TTM earnings before interest & taxes is currently -$99.13 million, with the most recent change of -$2.79 million (-2.89%) on 30 September 2024. Over the past year, it has dropped by -$9.14 million (-10.15%). URGN TTM EBIT is now -2354.91% below its all-time high of $4.40 million, reached on 31 December 2016.URGN TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
URGN EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +16.1% | -15.4% | -10.2% |
| 3 y3 years | +34.0% | +30.9% | +9.5% |
| 5 y5 years | -8.3% | +11.1% | -5.8% |
URGN EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +34.0% | -15.4% | +30.9% | -18.6% | +10.9% |
| 5 y | 5 years | -8.3% | +34.0% | -15.4% | +47.6% | -18.6% | +28.9% |
| alltime | all time | <-9999.0% | +34.0% | -250.1% | +47.6% | -2354.9% | +28.9% |
UroGen Pharma EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$20.86 M(-30.2%) | -$99.13 M(+2.9%) |
| June 2024 | - | -$29.90 M(+0.4%) | -$96.34 M(+11.0%) |
| Mar 2024 | - | -$29.79 M(+60.3%) | -$86.75 M(+3.8%) |
| Dec 2023 | -$83.61 M(-16.0%) | -$18.58 M(+2.8%) | -$83.61 M(-7.1%) |
| Sept 2023 | - | -$18.07 M(-11.1%) | -$89.99 M(-4.6%) |
| June 2023 | - | -$20.32 M(-23.7%) | -$94.34 M(-4.2%) |
| Mar 2023 | - | -$26.64 M(+6.7%) | -$98.44 M(-1.2%) |
| Dec 2022 | -$99.59 M(-8.9%) | -$24.96 M(+11.3%) | -$99.59 M(-2.3%) |
| Sept 2022 | - | -$22.43 M(-8.2%) | -$101.95 M(-7.1%) |
| June 2022 | - | -$24.42 M(-12.1%) | -$109.73 M(-1.3%) |
| Mar 2022 | - | -$27.79 M(+1.7%) | -$111.22 M(+1.5%) |
| Dec 2021 | -$109.37 M(-13.7%) | -$27.32 M(-9.6%) | -$109.55 M(+0.1%) |
| Sept 2021 | - | -$30.21 M(+16.6%) | -$109.49 M(+1.0%) |
| June 2021 | - | -$25.91 M(-0.8%) | -$108.40 M(-5.2%) |
| Mar 2021 | - | -$26.11 M(-4.2%) | -$114.29 M(-9.8%) |
| Dec 2020 | -$126.74 M | -$27.25 M(-6.4%) | -$126.74 M(-9.0%) |
| Sept 2020 | - | -$29.12 M(-8.4%) | -$139.32 M(+4.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2020 | - | -$31.80 M(-17.5%) | -$133.65 M(+6.4%) |
| Mar 2020 | - | -$38.56 M(-3.2%) | -$125.61 M(+14.7%) |
| Dec 2019 | -$109.48 M(+41.8%) | -$39.84 M(+69.9%) | -$109.48 M(+16.9%) |
| Sept 2019 | - | -$23.45 M(-1.3%) | -$93.66 M(+2.6%) |
| June 2019 | - | -$23.75 M(+5.9%) | -$91.29 M(+6.2%) |
| Mar 2019 | - | -$22.43 M(-6.6%) | -$85.97 M(+11.4%) |
| Dec 2018 | -$77.18 M(+286.9%) | -$24.02 M(+13.9%) | -$77.18 M(+21.9%) |
| Sept 2018 | - | -$21.09 M(+14.4%) | -$63.32 M(+48.9%) |
| June 2018 | - | -$18.43 M(+35.1%) | -$42.53 M(+41.5%) |
| Mar 2018 | - | -$13.64 M(+34.3%) | -$30.05 M(+50.6%) |
| Dec 2017 | -$19.95 M(-2600.0%) | -$10.16 M(+3252.5%) | -$19.95 M(-585.5%) |
| Sept 2017 | - | -$303.00 K(-94.9%) | $4.11 M(-342.0%) |
| June 2017 | - | -$5.95 M(+68.2%) | -$1.70 M(-297.9%) |
| Mar 2017 | - | -$3.54 M(-125.5%) | $858.00 K(-80.5%) |
| Dec 2016 | $798.00 K(-106.4%) | $13.90 M(-327.5%) | $4.40 M(-146.2%) |
| Sept 2016 | - | -$6.11 M(+80.0%) | -$9.51 M(+180.0%) |
| June 2016 | - | -$3.40 M | -$3.40 M |
| Dec 2015 | -$12.41 M | - | - |
FAQ
- What is UroGen Pharma annual earnings before interest & taxes?
- What is the all time high annual EBIT for UroGen Pharma?
- What is UroGen Pharma annual EBIT year-on-year change?
- What is UroGen Pharma quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for UroGen Pharma?
- What is UroGen Pharma quarterly EBIT year-on-year change?
- What is UroGen Pharma TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for UroGen Pharma?
- What is UroGen Pharma TTM EBIT year-on-year change?
What is UroGen Pharma annual earnings before interest & taxes?
The current annual EBIT of URGN is -$83.61 M
What is the all time high annual EBIT for UroGen Pharma?
UroGen Pharma all-time high annual earnings before interest & taxes is $1.01 M
What is UroGen Pharma annual EBIT year-on-year change?
Over the past year, URGN annual earnings before interest & taxes has changed by +$15.98 M (+16.05%)
What is UroGen Pharma quarterly earnings before interest & taxes?
The current quarterly EBIT of URGN is -$20.86 M
What is the all time high quarterly EBIT for UroGen Pharma?
UroGen Pharma all-time high quarterly earnings before interest & taxes is $13.90 M
What is UroGen Pharma quarterly EBIT year-on-year change?
Over the past year, URGN quarterly earnings before interest & taxes has changed by -$2.79 M (-15.43%)
What is UroGen Pharma TTM earnings before interest & taxes?
The current TTM EBIT of URGN is -$99.13 M
What is the all time high TTM EBIT for UroGen Pharma?
UroGen Pharma all-time high TTM earnings before interest & taxes is $4.40 M
What is UroGen Pharma TTM EBIT year-on-year change?
Over the past year, URGN TTM earnings before interest & taxes has changed by -$9.14 M (-10.15%)